Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06369298 · ClinicalTrials.gov registry record · Phase 2

Study of JK07 in Patients With Chronic Heart Failure

A Phase 2 study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, sponsored by Salubris Biotherapeutics.

Recruiting
Registry status
Phase 2
Development phase
282
Enrollment target
20
Study locations

NCT06369298 is a Phase 2 study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction that is actively recruiting participants, run by Salubris Biotherapeutics. The registered enrollment target is 282 participants, below the 2,282-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (88% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06369298, a Phase 2 study of Heart Failure With Preserved Ejection Fraction and Heart Failure With Reduced Ejection Fraction, is actively recruiting participants, sponsored by Salubris Biotherapeutics.

RECRUITING
Registry status
Phase 2
Development phase
282 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) of ≤ 40%. Cohort 2: Heart failure (HF) participants with left ventricular ejection fraction (LVEF) \> 40% and ≤ 65%.

Conditions Studied

Heart Failure With Preserved Ejection Fraction Heart Failure With Reduced Ejection Fraction

Interventions

  • DRUG Placebo
  • DRUG JK07

Study Locations (20)

California

  • Site 128 - Huntington Beach
  • Site 157 - Los Angeles
  • Site 158 - Orange
  • Site 116 - Pasadena
  • Site 129 - Santa Maria
  • Site 102 - Stanford
  • Site 113 - Torrance
  • Site 133 - Vista

Alabama

  • Site 121 - Alexander City
  • Site 130 - Birmingham
  • Site 139 - Birmingham
  • Site 138 - Huntsville

Florida

  • Site 161 - Coral Gables
  • Site 114 - Hialeah
  • Site 162 - Miami Lakes
  • Site 159 - Naples

Arizona

  • Site 111 - Phoenix

Arkansas

  • Site 127 - Little Rock

Georgia

  • Site 136 - Atlanta

Idaho

  • Site 143 - Boise

Trial Details

FieldValue
Enrollment Target 282 participants
Start Date 2024-03-28
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

Salubris Biotherapeutics

3 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06369298

The ClinicalTrials.gov registry entry for NCT06369298 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,282-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (88% lower). The listed sponsor is Salubris Biotherapeutics, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06369298 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Alabama, Florida.

Frequently Asked Questions

What is clinical trial NCT06369298 about?

NCT06369298 is a clinical study titled "Study of JK07 in Patients With Chronic Heart Failure". This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure. There will be 2 cohorts in this study: Cohort 1: Heart failure (HF) participants with left ventricular ejecti...

What is the current status of trial NCT06369298?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 282 participants. The study started on 2024-03-28. Estimated completion is 2026-06-30.

What conditions does trial NCT06369298 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction.

What interventions are being tested in trial NCT06369298?

The interventions under investigation include: Placebo (DRUG), JK07 (DRUG).

Who is sponsoring clinical trial NCT06369298?

This trial is sponsored by Salubris Biotherapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06369298 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Heart Failure With Preserved Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Heart Failure With Preserved Ejection Fraction

All registered trials for this condition

Heart Failure With Reduced Ejection Fraction

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.